ALN-GO1 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
234	ペルオキシソーム病（副腎白質ジストロフィーを除く。）	21

234. ペルオキシソーム病（副腎白質ジストロフィーを除く。）

臨床試験数 : 39 / 薬物数 : 35 - (DrugBank : 12) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45

diseases per page:

Showing 1 to 10 of 21 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001346-17-IT (EUCTR)	14/05/2021	07/06/2021	A Phase 3 study of an Investigational Drug, Lumasiran (ALN-GO1) in patients with advanced primary hy ...	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: [ALN-GO1] INN or Proposed INN: Lumasiran	ALNYLAM PHARMACEUTICALS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 3	United Arab Emirates;United States;Lebanon;Turkey;Israel;United Kingdom;Switzerland;Italy;India;Egyp ...
2	EUCTR2019-001346-17-GB (EUCTR)	22/01/2020	23/07/2019	A Phase 3 study of an Investigational Drug, Lumasiran (ALN-GO1) in patients with advanced primary hy ...	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: Lumasiran	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	16	Phase 3	United Arab Emirates;United States;Lebanon;Turkey;Israel;United Kingdom;Switzerland;India;Egypt;Fran ...
3	EUCTR2019-001346-17-NL (EUCTR)	05/12/2019	22/08/2019	A Phase 3 study of an Investigational Drug, Lumasiran (ALN-GO1) in patients with advanced primary hy ...	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: LUMASIRAN	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	16	Phase 3	United States;United Arab Emirates;Lebanon;Turkey;Israel;Switzerland;United Kingdom;India;Egypt;Fran ...
4	EUCTR2019-001346-17-BE (EUCTR)	07/10/2019	21/08/2019	A Phase 3 study of an Investigational Drug, Lumasiran (ALN-GO1) in patients with advanced primary hy ...	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: LUMASIRAN	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	16	Phase 3	United States;Egypt;United Kingdom;United Arab Emirates;Switzerland;India;Lebanon;Netherlands;Turkey ...
5	EUCTR2018-004014-17-DE (EUCTR)	23/04/2019	27/12/2018	A Study of an Investigational Drug, Lumasiran (ALN-GO1) in Infants and Young Children with Primary H ...	ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacody ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: LUMASIRAN	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 3	France;United States;Israel;Germany;United Kingdom
6	EUCTR2018-001981-40-NL (EUCTR)	21/03/2019	21/01/2019	A Phase 3 Study of an Investigational Drug, Lumasiran (ALN-GO1) with an Extended Dosing Period in Ch ...	ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study with an Extended Dosing P ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: lumasiran	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 3	France;United States;United Arab Emirates;Jordan;Israel;Germany;Netherlands;United Kingdom;Japan;Swi ...
7	EUCTR2018-004014-17-GB (EUCTR)	01/03/2019	19/12/2018	A Study of an Investigational Drug, Lumasiran (ALN-GO1) in Infants and Young Children with Primary H ...	ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacody ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: LUMASIRAN	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;United States;Israel;Germany;United Kingdom
8	EUCTR2018-004014-17-FR (EUCTR)	19/02/2019	26/12/2018	A Study of an Investigational Drug, Lumasiran (ALN-GO1) in Infants and Young Children with Primary H ...	ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacody ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: LUMASIRAN	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	8	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;France;Israel;Germany;United Kingdom
9	EUCTR2018-001981-40-DE (EUCTR)	17/12/2018	11/09/2018	A Phase 3 Study of an Investigational Drug, Lumasiran (ALN-GO1) with an Extended Dosing Period in Ch ...	ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study with an Extended Dosing P ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: lumasiran	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 3	France;United States;United Arab Emirates;Jordan;Israel;Netherlands;Germany;Switzerland;United Kingd ...
10	EUCTR2018-001981-40-GB (EUCTR)	20/11/2018	07/08/2018	A Phase 3 Study of an Investigational Drug, Lumasiran (ALN-GO1) with an Extended Dosing Period in Ch ...	ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study with an Extended Dosing P ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: lumasiran	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	39	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;United States;United Arab Emirates;Jordan;Israel;Netherlands;Germany;Switzerland;United Kingd ...

First Previous1 2 3Next Last